Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02064582 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
A Phase 2 study of Prostate Cancer, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT02064582: Completed Phase 2 study of Prostate Cancer, sponsored by University of Texas Southwestern Medical Center.
NCT02064582 is a Phase 2 study of Prostate Cancer that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 7 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02064582, a Phase 2 study of Prostate Cancer, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is being done to find out whether combining two FDA approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.
Primary Outcome
Assessment will number of participants who experience adverse events greater than or equal to Grade 3, as defined by NCI Common terminology criteria for adverse events(CTCAE) v4.0
Conditions Studied
Interventions
- DRUG Leuprolide acetate
- DRUG Enzalutamide
- RADIATION radiation
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-05 |
| Est. Completion | 2018-06-09 |
| Phase | Phase 2 |
What the finished NCT02064582 record still lists
NCT02064582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Leuprolide acetate is the first listed.
NCT02064582 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02064582 about?
NCT02064582 is a clinical study titled "Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer". The study is being done to find out whether combining two FDA approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.
What is the current status of trial NCT02064582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2014-05. Estimated completion is 2018-06-09.
What conditions does trial NCT02064582 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02064582?
The interventions under investigation include: Leuprolide acetate (DRUG), Enzalutamide (DRUG), radiation (RADIATION).
Who is sponsoring clinical trial NCT02064582?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02064582 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02064582's enrollment target sits among peer trials
7 729th of 735 higher than 6 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia